Banjak Marc 4

What Happened
Marc Banjak, Chief Legal Officer of iBio, was granted a derivative award on Jan 28, 2026 covering 146,000 shares (reported as acquired at $0.00). The Form 4 lists this as an award/grant of derivative securities (transaction code A). The filing does not show any cash paid; this is a compensation equity award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-28 (Form 4 filed 2026-01-30; appears timely).
• Transaction type/code: Award/Grant (A) of derivative securities (options/rights) for 146,000 shares; acquisition price on form: $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote (vesting): 25% vests on the one‑year anniversary of the grant; the remaining 75% vests in equal quarterly installments over the next 36 months, contingent on continued employment.
• No indication of immediate exercise or sale of underlying shares in this filing.

Context
This filing reports an equity compensation grant (an award of derivative securities) rather than a market trade. Such grants are typically part of executive compensation and do not by themselves indicate buying or selling in the market. The $0.00 figure reflects the reporting of the award on the Form 4 and does not represent market value realized by the insider.